SeaStar Medical Q2 Revenue Jumps 82% as Pediatric AKI Device Gains Traction
ICU sits 62% above its 52-week low of $2.07.
Summary
SeaStar Medical reported Q2 2026 net revenue of $0.6M, up 82% year-over-year, driven by three new top-rated children's hospital customers for its QUELIMMUNE pediatric AKI device. Gross margins held at 91%. The company also advanced its NEUTRALIZE-AKI pivotal trial to 223 of 339 enrolled adult patients, with enrollment completion expected around year-end or early 2027. New ICD-10-PCS billing codes take effect October 1, 2026, which should streamline hospital reimbursement. The company remains in a going-concern situation with less than 12 months of cash, so the revenue growth and trial progress are critical to its survival.
Updates
· SEC 10-Q — Cash fell to $7.0M at June 30, 2026 from $12.0M at year-end 2025; net loss was $7.3M for H1 2026.
At the time of this announcement, ICU was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $2.07 to $12.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.